RxDoctor Payments Data

Paul Oczypok, MD

Internal Medicine · Pittsburgh, PANPI 1679564371

Payments from drug & device makers

$130in general payments, 2019–2025

Across 10 payments — averaging $13.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$37
  • Novo Nordisk$27
  • UCB, Inc.$21
  • GSK$12
  • Vivus LLC$12
  • AbbVie$11
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$37
Novo Nordisk1$27
UCB, Inc.1$21
GSK1$12
Vivus LLC3$12
AbbVie1$11
Merck1$11

How this compares

$130 in reported general payments places this provider in the 45th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$67,352
Medicare patients
133
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$161,916
JardianceEmpagliflozin84$97,670
TrulicityDulaglutide56$65,001
XareltoRivaroxaban26$32,075
JanuviaSitagliptin Phosphate28$31,909
Erythromycin Ethylsuccinate101$26,670
Lansoprazole102$22,215
PrevacidLansoprazole38$21,618
OzempicSemaglutide21$21,506
Potassium Chloride156$20,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,585
LinzessLinaclotide26$15,883
Breo ElliptaFluticasone/Vilanterol21$14,649
Combivent RespimatIpratropium/Albuterol Sulfate26$13,530
Scopolamine188$11,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$37$165,845167 claims
GSKTrelegy Ellipta, Breo Ellipta$12$32,23447 claims
MerckJanuvia$11$31,90928 claims
Novo NordiskOzempic$27$21,50621 claims
AbbVieLinzess, Creon$11$19,732107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →